Big Gain For Clarus Therapeutics Holdings Inc.
Mon, Mar 21, 2022 at 05:30 PM

Clarus Therapeutics Holdings Inc. (CRXT:NASDAQ) soared at $1.22, representing a gain of 58.4%. On Fri, Mar 18, 2022, CRXT:NASDAQ hit a New 2-Week High of $0.77. The stock appeared on our News Catalysts scanner on Wed, Mar 16, 2022 at 10:01 AM in the 'BIOTECH' category. From Mon, Mar 07, 2022, the stock recorded 66.67% Up Days and 60.00% Green Days
About Clarus Therapeutics Holdings Inc. (CRXT:NASDAQ)
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications.
Top 10 Gainers:
- NeuroSense Therapeutics Ltd. (NRSN:NASDAQ), 299.36%
- Clarus Therapeutics Holdings Inc. (CRXT:NASDAQ), 58.44%
- Yumanity Therapeutics Inc. (YMTX:NASDAQ), 58.04%
- BitNile Holdings Inc. (NILE:NYSEMKT), 48.56%
- UTime Limited (UTME:NASDAQ), 44.79%
- Dermata Therapeutics Inc. (DRMA:NASDAQ), 44%
- CYREN Ltd. (CYRN:NASDAQ), 43.22%
- PainReform Ltd. (PRFX:NASDAQ), 39.64%
- Corbus Pharmaceuticals Holdings, Inc. (CRBP:NASDAQ), 38.02%
- O2Micro International Limited (OIIM:NASDAQ), 34.37%